Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 77.5% in July

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 4,548 shares, a drop of 77.5% from the June 30th total of 20,244 shares. Based on an average trading volume of 29,911 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cardio Diagnostics in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Cardio Diagnostics Stock Performance

Shares of CDIO traded down $0.08 during midday trading on Friday, hitting $1.55. 1,219,129 shares of the stock were exchanged, compared to its average volume of 28,589. Cardio Diagnostics has a 52-week low of $0.97 and a 52-week high of $7.91. The stock has a fifty day simple moving average of $1.87 and a 200 day simple moving average of $2.18. The firm has a market cap of $4.59 million, a P/E ratio of -0.46 and a beta of 2.23.

Cardio Diagnostics (NASDAQ:CDIO) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.63) earnings per share for the quarter. Cardio Diagnostics had a negative net margin of 36,950.00% and a negative return on equity of 78.82%.

Institutional Investors Weigh In On Cardio Diagnostics

Several institutional investors have recently added to or reduced their stakes in CDIO. Citadel Advisors LLC acquired a new stake in shares of Cardio Diagnostics in the third quarter valued at about $79,000. DRW Securities LLC grew its position in Cardio Diagnostics by 122.8% during the fourth quarter. DRW Securities LLC now owns 40,463 shares of the company’s stock worth $110,000 after buying an additional 22,298 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Cardio Diagnostics in the first quarter valued at about $30,000. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.